Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?
| Autor: | Marques C; Centro Hospitalar de Vila Nova de Gaia Espinho EPE, Vila Nova de Gaia, Portugal., Ferreira da Silva F; Champalimaud Foundation, Lisboa, Portugal filipa.silva@fundacaochampalimaud.pt., Sousa I; Centro Hospitalar Universitário de São João, Porto, Portugal.; Faculty of Medicine of the University of Porto, Porto, Portugal., Nave M; Hospital da Luz, Lisboa, Portugal.; Nova Medical School, Lisbon, Portugal. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2023 Apr 03; Vol. 33 (4), pp. 607-618. Date of Electronic Publication: 2023 Apr 03. |
| DOI: | 10.1136/ijgc-2022-003719 |
| Abstrakt: | Advanced ovarian cancer remains a leading cause of death from gynecologic malignancy. Surgery and, in most cases, platinum-based chemotherapy with or without maintenance with bevacizumab and/or poly-ADP ribose polymerase inhibitors (PARPi) represent the mainstay of treatment, but the disease typically recurs. The treatment of these patients represents a clinical challenge because sequential chemotherapy regimens are often used, with suboptimal outcomes and cumulative toxicity. Chemotherapy-free regimens, based on combinations of PARPi, vascular endothelial growth factor receptor inhibitors, anti-programmed cell death protein-1/programmed death-ligand 1, and anti-cytotoxic T-lymphocyte-associated protein-4 antibodies, among others, represent a valid option, with manageable toxicity profile and ease of administration. This review addresses this new strategy in the management of recurrent ovarian cancer and discusses its feasibility in the treatment landscape of the disease. Competing Interests: Competing interests: CM received honoraria from GSK, Astra Zeneca, MSD, and Pfizer. IS received honoraria from Astra Zeneca, GSK, MSD, and Pfizer. FFdS received honoraria from Astra Zeneca, GSK, and MSD. MN received honoraria from Astra Zeneca, GSK, MSD, and Pfizer. (© IGCS and ESGO 2023. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|